Obiettivo Alzheimer's disease (AD) is one of the most common neurodegenerative disorders, which currently affects 4 million subjects in the European Union. The prevalence of AD is expected to increase substantially the next decades due to the aging population. AD severely affects the quality of life of patients and their relatives. It also poses a major burden to the health care system. Abnormalities in beta amyloid processing are a key feature of the disease. Therapeutic strategies, which modify beta amyloid processing, are currently under development. The development of these drugs, however, is hampered by the lack of accurate diagnostic criteria for AD in the early stage and the lack of potential markers of treatment response. Recent studies indicated that beta amyloid oligomers play an important role in the early pathophysiology of AD. The aim of the present project is to investigate whether beta amyloid oligomers in cerebrospinal fluid, plasma, and serum can be used for the early diagnosis of AD and whether they can be used as a marker of treatment response. In it will be investigated whether genes known to be involved in beta amyloid processing influence levels of these markers.Oligomers will be measured using two techniques. The first is based on ultrasensitive immuno-polymerase chain reaction and will be developed during the project. The second is based on a combination of immunoprecipitation and ELISA and has already been developed by one of the partners. Measurements will be performed in cerebrospinal fluid, serum, and plasma samples of 100 subjects with AD, 250 subjects with mild cognitive impairment (a prodromal stage of AD), 100 subjects with other types of dementia, and 50 control subjects. In order to investigate the potential of beta amyloid oligomers to be used as marker of treatment response, cerebrospinal fluid samples and blood samples will be collected 9 and 18 months after baseline in 60 subjects with AD and 60 with mild cognitive impair Campo scientifico medical and health sciencesbasic medicineneurologydementiaalzheimermedical and health sciencesbasic medicinephysiologypathophysiology Programma(i) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Argomento(i) LSH-2005-1.2.2-2 - Development of innovative methods for diagnosis of nervous system disorders Invito a presentare proposte FP6-2005-LIFESCIHEALTH-6 Vedi altri progetti per questo bando Meccanismo di finanziamento STREP - Specific Targeted Research Project Coordinatore VRIJE UNIVERSITEIT MEDICAL CENTRE Contributo UE Nessun dato Indirizzo De Boelelaan 1117 AMSTERDAM Paesi Bassi Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato Partecipanti (13) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto CHIMERA BIOTECH GMBH Germania Contributo UE Nessun dato Indirizzo Kurfürstenallee 23a BREMEN Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato HYCULT BIOTECHNOLOGY B.V. Paesi Bassi Contributo UE Nessun dato Indirizzo Frontstraat 2A, 5405 PB UDEN Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato ACADEMISCH MEDISCH CENTRUM/UNIVERSITEIT VAN AMSTERDAM Paesi Bassi Contributo UE Nessun dato Indirizzo Meibergdreef 9 AMSTERDAM Mostra sulla mappa Costo totale Nessun dato KAROLINSKA INSTITUTET Svezia Contributo UE Nessun dato Indirizzo Inst Neurotec, Karolinska Universitetssjukhuset, Novum plan 5 HUDDINGE Mostra sulla mappa Costo totale Nessun dato ARISTOTLE UNIVERSITY OF THESSALONIKI Grecia Contributo UE Nessun dato Indirizzo Administration Building - University Campus THESSALONIKI Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato KATHOLIEKE UNIVERSITEIT LEUVEN Belgio Contributo UE Nessun dato Indirizzo Oude Markt 13 LEUVEN Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato RIGSHOSPITALET Danimarca Contributo UE Nessun dato Indirizzo Blegdamsvej 9 COPENHAGEN Mostra sulla mappa Costo totale Nessun dato UNIVERSITY OF MAASTRICHT Paesi Bassi Contributo UE Nessun dato Indirizzo Minderbroedersberg 4-6 MAASTRICHT Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato ABBOTT GMBH& CO.KG Germania Contributo UE Nessun dato Indirizzo Knollstraße 50 LUDWIGSHAFEN Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato GREEK ASSOCIATION OF ALZHEIMER'S DISEASE AND RELATED DISORDERS Grecia Contributo UE Nessun dato Indirizzo Petrou Syndica 13 THESSALONIKI Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT Germania Contributo UE Nessun dato Indirizzo J5 MANNHEIM Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato FORSCHUNGSZENTRUM JÜLICH GMBH Germania Contributo UE Nessun dato Indirizzo Leo Brandt Strasse JÜLICH Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato LUDWIG MAXIMILIAN UNIVERSITY OF MUNICH CLINIC OF PSYCHIATRY AND PSYCHOTHERAPY Germania Contributo UE Nessun dato Indirizzo Nussbaumstr. 7 MUNICH Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato